Exelixis Inc.is gearing up to file cabozantinib for early FDA approval for frontline metastatic kidney cancer after releasing strong results in the Phase II CABOSUN study, but the market has the jitters about whether a Phase III study will be needed.
Exelixis released positive full results from the eagerly awaited Phase II CABOSUN first-line metastatic RCC study at the European Society...






